Russia acts to prevent anti-HIV drugs shortages in domestic market

The Russian government is planning to take measures to prevent a shortage of anti-HIV drugs in the country by the increased procurements drugs and their more active supplies to the domestic market, reports The Pharma Letter’s local correspondent.

Recently Russian media reported about the shortage of Tivicay (dolutegravir), an anti-HIV drugs from the UK’s GSK (LSE: GSK) in the Russian market, which is mainly due to a significant decline of the volume of its procurements by the state.

According to analysts, as of now, patients in different regions of Russia, have faced shortage of dolutegravir (DTG), which has no analogues in Russia.